BoneXpert
Visiana · Decision date Sep 22, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for BoneXpert, a Visiana premarket notification assigned K262390, with a decision date of September 22, 2026 and receipt date of July 13, 2026. The device is classified under 21 CFR 892.2050 as a medical image management and processing system, Class II, product code QIH, in the radiology specialty. SESE denotes 510(k) clearance, not premarket approval.
The submission describes DICOM software that estimates bone age from posterior-anterior pediatric hand radiographs using machine learning and the Greulich-Pyle method, returning an annotated image for radiologist review. The stated predicate is EFAI Bonesuite XR Bone Age Pro Assessment System (K234042); the summary notes differences in algorithm type and accepted hand laterality. The summary cites a Stanford multicenter study of 1,285 images from five U.S. sites, but the provided excerpts give no performance results, and the full indications enclosure is only partially legible.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262390
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Visiana
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
FDA decision timeline
K262390 received
Application receipt date recorded by FDA.
K262390 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
CINA-Aneurysm+K262147 | AVICENNA.AI | 510(k) clearance | Oct 19, 2026 | FDA |
Ligence HeartK261733 | UAB Ligence | 510(k) clearance | Oct 7, 2026 | FDA |
NeuroDRK262134 | Deep Reasoning Ai, Inc. | 510(k) clearance | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Visiana
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Horsholm
Sources and methodology
- Original FDA record: K262390
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


